Should evolocumab (Repatha) be added for a patient with coronary artery disease and peripheral vascular disease who has LDL‑C 75 mg/dL while on exenatide 10 mg daily and atorvastatin 80 mg daily?

Yes, add Repatha (evolocumab) to this patient's regimen

Despite achieving an LDL-C of 75 mg/dL on atorvastatin 80 mg, this patient with both CAD and PVD has not reached the guideline-recommended target of <55 mg/dL (<1.4 mmol/L) for very high-risk patients, and adding a PCSK9 inhibitor is specifically recommended by current guidelines for this exact scenario 1.

Why This Patient Qualifies for PCSK9 Inhibitor Therapy

Guideline-Based Rationale

The 2024 ESC Guidelines for chronic coronary syndromes provide clear direction 1:

• Target LDL-C for very high-risk patients (which includes those with established CAD and PVD): <55 mg/dL with ≥50% reduction from baseline
• Current LDL-C of 75 mg/dL exceeds this target by 20 mg/dL
• The guidelines explicitly state: "For patients who do not achieve their goal on a maximum tolerated dose of statin and ezetimibe, combination with a PCSK9 inhibitor is recommended" (Class I, Level A) 1

Treatment Algorithm Position

This patient is on:

1. ✓ Maximum-intensity statin (atorvastatin 80 mg) - first-line achieved
2. ✗ Missing ezetimibe - should ideally be added first
3. → PCSK9 inhibitor indicated if goal still not met

Important caveat: The guidelines technically recommend adding ezetimibe before PCSK9 inhibitors 1. However, given that:

• Ezetimibe typically reduces LDL-C by an additional 20-25% 1
• This would bring LDL-C from 75 mg/dL to approximately 56-60 mg/dL
• This still may not achieve the <55 mg/dL target
• The patient has dual vascular beds affected (CAD + PVD), placing them at exceptionally high risk

Evidence for Benefit in This Specific Population

Peripheral Artery Disease Subgroup Analysis

The FOURIER trial specifically demonstrated robust benefits in patients with PVD 2:

• Primary endpoint reduction: HR 0.79 (95% CI 0.66-0.94, P=0.0098)
• Key secondary endpoint: HR 0.73 (95% CI 0.59-0.91, P=0.0040)
• Absolute risk reduction of 3.5% for both endpoints - substantially higher than patients without PAD (1.4-1.6%)
• Major adverse limb events reduced: HR 0.58 (95% CI 0.38-0.88, P=0.0093) 2

Efficacy at Baseline LDL-C <70 mg/dL

Critical data from FOURIER subanalysis 3:

• Evolocumab was equally effective in patients with baseline LDL-C <70 mg/dL (HR 0.80) versus ≥70 mg/dL (HR 0.86)
• No interaction between baseline LDL-C and treatment effect (P=0.65)
• This directly addresses your patient's current LDL-C of 75 mg/dL

Expected LDL-C Reduction

Based on FDA label data and clinical trials 4, 5:

• Evolocumab added to atorvastatin 80 mg reduces LDL-C by an additional 63-71%
• From current LDL-C of 75 mg/dL, this would achieve approximately 22-28 mg/dL
• Well below the <55 mg/dL target

Practical Implementation

Dosing Options

• Evolocumab 140 mg subcutaneously every 2 weeks, OR
• Evolocumab 420 mg subcutaneously once monthly

Both regimens produce equivalent LDL-C reductions 4, 5.

Safety Profile

• Adverse events comparable to placebo (36% vs 39%) 5
• Most common: injection site reactions, back pain, arthralgia (all <2%)
• No safety concerns at very low LDL-C levels achieved 3
• Long-term safety demonstrated up to 8.4 years 6

Alternative Consideration: Sequential Approach

If cost or access is a barrier, consider:

1. Add ezetimibe 10 mg first (expected LDL-C reduction to ~56-60 mg/dL)
2. Reassess LDL-C in 4-6 weeks
3. Add evolocumab if still >55 mg/dL

However, given this patient's dual high-risk features (CAD + PVD) and the 2018 ESC guidance suggesting lower thresholds for PCSK9 inhibitors in patients with "severe and/or extensive ASCVD" 7, proceeding directly to evolocumab is justified, particularly if the patient has had recent events or progressive disease.

Key Clinical Pitfalls to Avoid

• Don't delay intensification: The benefit of evolocumab grows over time, with greater absolute risk reductions emerging after several years 8
• Don't assume "good enough": An LDL-C of 75 mg/dL, while improved, leaves substantial residual risk in this very high-risk patient
• Don't forget adherence: Verify the patient is actually taking atorvastatin 80 mg daily before adding therapy 7
• Don't ignore the limb benefit: The reduction in major adverse limb events is clinically meaningful for PVD patients 2

The combination of established CAD, PVD, and LDL-C above target on maximum statin therapy creates a compelling indication for PCSK9 inhibitor therapy based on the highest-quality guideline recommendations and robust clinical trial evidence 1, 2.